Document Detail


Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
MedLine Citation:
PMID:  16956836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Authors:
Jan Samuelsson; Manuel Mutschler; Gunnar Birgegård; Poul Gram-Hansen; Magnus Björkholm; Heike L Pahl
Related Documents :
17075396 - Increased polymorphism in the hr-1 gp41 env gene encoding the enfuvirtide (t-20) target...
18398736 - Jak2 v617f patients with essential thrombocythemia present with clinical features of po...
21541226 - Detrusor arreflexia as an end stage of neurogenic bladder in ham/tsp?
20413436 - Correlation of kidney function, volume and imaging findings, and pkhd1 mutations in 73 ...
24719536 - Usefulness of right atrial volume index in predicting outcome in chronic systolic heart...
17720726 - Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropath...
Publication Detail:
Type:  Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Haematologica     Volume:  91     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-07     Completed Date:  2006-10-24     Revised Date:  2014-07-08    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1281-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Female
Humans
Interferon-alpha / therapeutic use*
Janus Kinase 2
Male
Middle Aged
Mutation
Myeloproliferative Disorders / drug therapy*,  enzymology,  genetics*
Polycythemia Vera / drug therapy,  enzymology,  genetics
Polyethylene Glycols
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / genetics*
Recombinant Proteins
Thrombocythemia, Essential / drug therapy,  enzymology,  genetics
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P01 CA108671/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Interferon-alpha; 0/Polyethylene Glycols; 0/Proto-Oncogene Proteins; 0/Recombinant Proteins; 0/peginterferon alfa-2b; 99210-65-8/interferon alfa-2b; EC 2.7.10.1/Protein-Tyrosine Kinases; EC 2.7.10.2/JAK2 protein, human; EC 2.7.10.2/Janus Kinase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular characterization of thalassemia intermedia in Indians.
Next Document:  A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.